A Canadian framework for managing prostate cancer during the COVID-19 pandemic: Recommendations from the Canadian Urologic Oncology Group and the Canadian Urological Association

Affiliations

¹ The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
² Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
³ Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada.
⁴ Department of Oncology, Division of Radiation Oncology, University of Alberta, Edmonton, AB, Canada.
⁵ Department of Medical Oncology, Sunnybrook Odette Cancer Centre, Toronto, ON, Canada.
⁶ Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
⁷ Department of Oncology, Division of Radiation Oncology, McGill University, Montreal QC, Canada.
⁸ Division of Urology, Department of Surgery, Université Laval, Quebec City, QC, Canada.
⁹ Division of Urology, McMaster University, Hamilton, ON, Canada.
¹⁰ Division of Hematology and Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
¹¹ Department of Radiation Oncology, CHUQ, Université Laval, Quebec City, QC, Canada.
¹² Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, Toronto, ON, Canada.
¹³ Department of Urology, Dalhousie University, Halifax, NS, Canada.

PMID: 32374715
PMCID: PMC7654681
DOI: 10.5489/cuaj.6667

A Canadian framework for managing prostate cancer during the COVID-19 pandemic: Recommendations from the Canadian Urologic Oncology Group and the Canadian Urological Association

Andrea Kokorovic et al. Can Urol Assoc J. 2020 Jun.

. 2020 Jun;14(6):163-168.

doi: 10.5489/cuaj.6667.

Authors

Affiliations

¹ The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
² Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
³ Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada.
⁴ Department of Oncology, Division of Radiation Oncology, University of Alberta, Edmonton, AB, Canada.
⁵ Department of Medical Oncology, Sunnybrook Odette Cancer Centre, Toronto, ON, Canada.
⁶ Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
⁷ Department of Oncology, Division of Radiation Oncology, McGill University, Montreal QC, Canada.
⁸ Division of Urology, Department of Surgery, Université Laval, Quebec City, QC, Canada.
⁹ Division of Urology, McMaster University, Hamilton, ON, Canada.
¹⁰ Division of Hematology and Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
¹¹ Department of Radiation Oncology, CHUQ, Université Laval, Quebec City, QC, Canada.
¹² Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, Toronto, ON, Canada.
¹³ Department of Urology, Dalhousie University, Halifax, NS, Canada.

PMID: 32374715
PMCID: PMC7654681
DOI: 10.5489/cuaj.6667

No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: Dr. So has been an advisory board member for Abbvie, Amgen, Astellas, Bayer, Janssen, Ferring, and TerSera; and has participated in clinical trials supported by Astellas, Ferring, and Janssen. Dr. Hotte has received honoraria from Astellas Scientific and Medical Affairs Inc, Bayer, Eisai Canada, and Janssen Oncology; has had a consulting or advisory role with Astellas Pharma; AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, Janssen, Merck, Pfizer, and Roche Canada; has received research funding from AstraZeneca, Ayala Pharmaceuticals, Bayer, Bristol-Myers Squibb, Clovis Oncology, Janssen Oncology, Merck, Pfizer (Inst), and Roche/Genentech; and has received travel, accommodations, and expenses from Eisai Canada. Dr. Black has been advisory board member or equivalent for Abbvie, Asieris, Astellas, AstraZeneca, Bayer, Biosyent, BMS, EMD-Serono, Fergene, H3-Biomedicine, Janssen, Merck, Roche, Sanofi, and Urogen; a speakers’ bureau member for Abbvie, Biosyent, Ferring, Janssen, Pfizer, and TerSera; has received grants and/or honoraria from Bayer, GSK, iProgen, and Sanofi; has participated in clinical trials supported by Astellas, AstraZeneca, BMS, Genentech, Janssen, MDx Health, Pacific Edge, Sitka, and Therelase; and shares a patent with Decipher Biosciences. Dr. Danielson has received advisory board honoraria and speaker fees from Amgen, Astellas, Bayer, and Janssen. Dr. Emmenegger. Dr. Finelli has been an advisory board member for Abbvie, Astellas, Bayer, Janssen, Ipsen, Sanofi, and TerSera; and has participated in clinical trials supported byAstellas, Bayer, and Janssen. Dr. Niazi has received research grants and honoraria from Abbvie, Amgen, Astellas, Astra Zeneca, Bayer, Janssen, and Sanofi; and has participated in clinical trials supported by Astellas, Ferring, Janssen, and Sanofi. Dr. Pouliot has been an advisory board member for Amgen, Astellas, Bayer, and Janssen; has received payment from Abbott, Amgen, Astellas, Astra Zeneca, Bayer, Ferring, Janssen, and Sanofi; has received grants from Astra Zeneca and Sanofi; and has participated in clinical trials supported by Astellas, Bayer, Ferring, and Janssen. Dr. Shayegan has been an advisory board member for Astellas, Bayer, and Janssen; and has received a research grant from Janssen. Dr. Sridhar has been an advisory board member for Astellas, AstraZeneca, Bayer, Janssen, Merck, and Roche; and has participated in several pharma-supported clinical trials. Dr. Vigneault has been an advisory board member for Abbvie, Bayer, Ferring, and Sanofi. Dr. Loblaw has been an advisory bpard members for Abbvie, Amgen, Astellas, Janssen, and Sanofi; and has received honoraria from AbbVie, Astellas, Amgen, AstraZeneca, Bayer, Janssen, Sanofi, and TerSera. Dr. Rendon has been an advisory board and speakers’ bureau member for, and has received honoraria from Abbvie, Amgen, Astellas, Astra Zeneca, Bayer, Ferring, Jansen, and Sanofi.

Cited by

Management of prostate cancer patients during COVID-19 pandemic.
Obek C, Doganca T, Argun OB, Kural AR. Obek C, et al. Prostate Cancer Prostatic Dis. 2020 Sep;23(3):398-406. doi: 10.1038/s41391-020-0258-7. Epub 2020 Jul 20. Prostate Cancer Prostatic Dis. 2020. PMID: 32690870 Free PMC article. Review.
The Evolving Clinical Management of Genitourinary Cancers Amid the COVID-19 Pandemic.
Izadmehr S, Lundon DJ, Mohamed N, Katims A, Patel V, Eilender B, Mehrazin R, Badani KK, Sfakianos JP, Tsao CK, Wiklund P, Oh WK, Cordon-Cardo C, Tewari AK, Galsky MD, Kyprianou N. Izadmehr S, et al. Front Oncol. 2021 Sep 27;11:734963. doi: 10.3389/fonc.2021.734963. eCollection 2021. Front Oncol. 2021. PMID: 34646777 Free PMC article. Review.
Cancer or COVID-19? A Review of Guidelines for Safe Cancer Care in the Wake of the Pandemic.
Gundavda MK, Gundavda KK. Gundavda MK, et al. SN Compr Clin Med. 2020;2(12):2691-2701. doi: 10.1007/s42399-020-00632-2. Epub 2020 Nov 21. SN Compr Clin Med. 2020. PMID: 33251481 Free PMC article. Review.
The effect of COVID-19 on prostate cancer testing in Australia.
Jain A, Macneil J, Kim L, Patel MI. Jain A, et al. BMC Urol. 2022 Jun 21;22(1):88. doi: 10.1186/s12894-022-01043-2. BMC Urol. 2022. PMID: 35729543 Free PMC article.
Prevalence and correlates of forgone care among adult Israeli Jews: A survey conducted during the COVID-19 outbreak.
Werner P, Tur-Sinai A. Werner P, et al. PLoS One. 2021 Nov 22;16(11):e0260399. doi: 10.1371/journal.pone.0260399. eCollection 2021. PLoS One. 2021. PMID: 34807948 Free PMC article.

See all "Cited by" articles

References

1. Bai Y, Yao L, Wei T, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA. 2020;323:1406–7. doi: 10.1001/jama.2020.2565. - DOI - PMC - PubMed
1. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China. Lancet Oncol. 2020;21:335–7. doi: 10.1016/S1470-2045(20)30096-6. - DOI - PMC - PubMed
1. Desai A, Sachdeva S, Parekh T, et al. COVID-19 and cancer: Lessons from a pooled meta-analysis. JCO Glob Oncol. 2020;6:557–9. doi: 10.1200/GO.20.00097. - DOI - PMC - PubMed
1. Lei S, Jiang F, Su W, et al. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. EClinicalMedicine. 2020 doi: 10.1016/j.eclinm.2020.100331. [Epub ahead of print]. - DOI - PMC - PubMed
1. Buriki TK. Cancer guidelines during the COVID-19 pandemic. Lancet Oncol. 2020 doi: 10.1016/S1470-2045(20)30217-5. [Epub ahead of print]. - DOI - PMC - PubMed

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

A Canadian framework for managing prostate cancer during the COVID-19 pandemic: Recommendations from the Canadian Urologic Oncology Group and the Canadian Urological Association

Affiliations

A Canadian framework for managing prostate cancer during the COVID-19 pandemic: Recommendations from the Canadian Urologic Oncology Group and the Canadian Urological Association

Authors

Affiliations

Conflict of interest statement

Similar articles

Cited by

References

LinkOut - more resources

Full Text Sources